Very exciting our shared disease potential treatment appears in a such a prestigious publication, which makes this novel drug seem quite real! It cannot be here soon enough for us to try to see if it makes some difference in our QoL. I know that airway clearance will remain our mainstay, with or without brensocatib, but perhaps with brensocatib will be reduced as fewer secretions will be produced.

Have you heard from anyone personally who's been in the study? I'm super curious how their day to day was changed or remained the same while on the trial. 25% reduction in exacerbations is not huge but it's something. I'll take it!